The report notes that the most common cancers vary between the developed and less developed world. In developed countries, breast, colorectal and lung cancer are the most common forms of the disease in women. While breast cancer is still number one in the less developed world, it is followed by cervical and stomach cancer. Among men, prostate, lung and colorectal cancers are most common in the developed world. In the less developed world, the most common cancers are of the stomach, lungs and liver.

Kava-kava tea, which is drunk as a relaxant in the Pacific island nations, contains elements which are thought to inhibit the formation of certain types of the disease including lung cancer.

Cuban scientists said on Tuesday the first vaccine to extend lives of lung cancer patients has been approved by Cuban authorities for use and is available in the island’s hospitals.The drug, CimaVax EGF, has been shown to increase survival rates on average four to five months and much longer in some patients, they said in a news conference at Cuba’s Center of Molecular Immunology.

In contrast to chemotherapy, the traditional treatment for lung cancer, they said CimaVax EGF has few side effects because it is a modified protein that attacks only cancer cells.

 Perceptronix is pleased to announce two (2) new distribution partnerships signifying an important third party validation of LungSign^TM and its value in the market place. IRS (Independent Respiratory Services) and Medpro Respiratory Care have agreed to add the LungSign^TM test kit to their list of offerings allowing physicians to now order the test directly through these service providers. Patients will receive a test kit, with a physician’s requisition, from our distributors’ office in their geographic area and then mail the specimen to the Perceptronix laboratory for analysis.

The Royal Australian College of General Practitioners (RACGP) has launched a new online learning activity designed to support general practitioners in boosting their knowledge about the latest approaches to the early detection of common types of cancer including breast cancer, cervical cancer, melanoma, lung cancer, ovarian cancer, prostate cancer and bowel cancer.

Eugene A. Woltering, MD, FACS, The James D. Rives Professor of Surgery and Chief of the Sections of Surgical Oncology & Endocrine Surgery at LSU Health Sciences Center New Orleans, has been awarded a US Patent for a one-step method to rapidly identify “sentinel nodes;” the lymph nodes most likely to contain early metastasis from a primary cancer. Preliminary research indicates that the procedure which consists of injection of a radiolabeled dye around a cancer can identify sentinel nodes that receive lymphatic drainage from the tumor within 10 minutes.

The foundation draws in £3m a year in grants and donations and it grants £1.5m out for research into the early detection of lung cancer.

Professor Ray Donnelly, founder and president of the Foundation, said: “The important thing is the current building, which was built for lung cancer research, will continue. However we have got too big for the administration, fundraising, and tobacco control staff.

“The university will now have more opportunity to move in other cancer specialists, creating a wonderful centre for cancer research.

Drs. Monica Mita and Francis Giles, at the University of Texas Health Science Center in San Antonio, are testing reovirus against bone and lung cancer.

The cancer in one of Mita’s experimental patients, Kenneth Scott, has remained stable since he received an experimental injection of Reolysin a year ago.

Thus, as Nexavar’s promise in treating kidney cancer became apparent in 2004, the stock, as noted, hit 60. But by late 2006 after Nexavar flopped in a Phase III trial for advanced skin cancer, shares could be had for $10 and change. Eleven months later, success in liver cancer made headlines and the stock shot up to over $60. But early this year, Nexavar failed a Phase III trial for lung cancer, sending shares plunging below $25. They now sell around $33, roughly half the recent high.

Holding your breath for 12 seconds is no big deal.Unless you’re a cancer patient.

“To some of them, it’s very long,” said Emily Oleneack, a technician displaying a $1.3 million CAT scan machine Sunday during Spectrum Health’s public opening of the Lemmen-Holton Cancer Pavilion.

Patients with lung cancer or those weakened by treatment will have to hold their breath for only up to six seconds as the “Lightspeed VCT” scans for tumors.